Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002361673 | SCV002658918 | likely pathogenic | Cardiovascular phenotype | 2023-10-10 | criteria provided, single submitter | clinical testing | The p.G214V variant (also known as c.641G>T), located in coding exon 5 of the ACVRL1 gene, results from a G to T substitution at nucleotide position 641. The glycine at codon 214 is replaced by valine, an amino acid with dissimilar properties. In our internal cohort, this variant was identified in an individual with a clinical diagnosis of hereditary hemorrhagic telangiectasia, presenting with epistaxis, telangiectasias, and a brain arteriovenous malformation (Ambry internal data). This variant has also been detected in an individual from a pulmonary arterial hypertension cohort (Zhu N et al. Genome Med. 2019 11;11(1):69)). Based on internal structural analysis, this variant disrupts the structure around the ATP-binding pocket in ACVRL1. In particular, it introduces a relatively bulky side chain into a highly conserved Gly-rich loop (Taylor SS et al. Trends Biochem. Sci., 2011 Feb;36:65-77), disrupting the local structure to a higher degree, and likely in a similar manner, as a known pathogenic variant in the same binding pocket. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Fulgent Genetics, |
RCV005008556 | SCV005637341 | likely pathogenic | Telangiectasia, hereditary hemorrhagic, type 2 | 2024-03-23 | criteria provided, single submitter | clinical testing |